Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Clinical Research Division, FHCC, Seattle, WA 98109, USA.
Immunity. 2023 Aug 8;56(8):1876-1893.e8. doi: 10.1016/j.immuni.2023.06.024. Epub 2023 Jul 21.
Acute graft-versus-host disease (aGVHD) remains a major limitation of allogeneic stem cell transplantation (SCT), and severe intestinal manifestation is the major cause of early mortality. Intestinal microbiota control MHC class II (MHC-II) expression by ileal intestinal epithelial cells (IECs) that promote GVHD. Here, we demonstrated that genetically identical mice of differing vendor origins had markedly different intestinal microbiota and ileal MHC-II expression, resulting in discordant GVHD severity. We utilized cohousing and antibiotic treatment to characterize the bacterial taxa positively and negatively associated with MHC-II expression. A large proportion of bacterial MHC-II inducers were vancomycin sensitive, and peri-transplant oral vancomycin administration attenuated CD4 T cell-mediated GVHD. We identified a similar relationship between pre-transplant microbes, HLA class II expression, and both GVHD and mortality in a large clinical SCT cohort. These data highlight therapeutically tractable mechanisms by which pre-transplant microbial taxa contribute to GVHD independently of genetic disparity.
急性移植物抗宿主病(aGVHD)仍然是异基因干细胞移植(SCT)的主要限制因素,严重的肠道表现是早期死亡的主要原因。肠道微生物群通过回肠肠上皮细胞(IECs)控制 MHC Ⅱ类(MHC-II)的表达,从而促进 GVHD。在这里,我们证明了不同供应商来源的遗传上相同的小鼠具有明显不同的肠道微生物群和回肠 MHC-II 表达,导致 GVHD 严重程度不一致。我们利用共笼和抗生素治疗来描述与 MHC-II 表达呈正相关和负相关的细菌分类群。MHC-II 诱导物的很大一部分细菌对万古霉素敏感,移植前口服万古霉素可减轻 CD4 T 细胞介导的 GVHD。在一个大型临床 SCT 队列中,我们发现了移植前微生物、HLA Ⅱ类表达以及 GVHD 和死亡率之间的类似关系。这些数据突出了治疗上可行的机制,即移植前微生物分类群通过与遗传差异无关的机制独立促进 GVHD。